Short Interest in Portage Biotech Inc. (NASDAQ:ALP) Decreases By 37.0%

Portage Biotech Inc. (NASDAQ:ALP) saw a significant decline in short interest in July. As of July 31st, there was short interest totaling 944,529 shares, a decline of 37.0% from the July 15th total of 1,498,532 shares. Approximately 4.0% of the shares of the stock are short sold. Based on an average daily volume of 3,047,112 shares, the days-to-cover ratio is presently 0.3 days.

Portage Biotech Trading Down 7.1%

Shares of Portage Biotech stock opened at $0.15 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 0.31 and a quick ratio of 0.31. Portage Biotech has a 1 year low of $0.14 and a 1 year high of $13.80. The company has a market capitalization of $3.54 million, a P/E ratio of -0.02 and a beta of 0.61. The business has a 50 day moving average price of $0.28 and a 200 day moving average price of $0.34.

Portage Biotech (NASDAQ:ALP) last posted its earnings results on Thursday, July 16th. The company reported $0.48 earnings per share (EPS) for the quarter. The company had revenue of $0.05 million during the quarter. Sell-side analysts anticipate that Portage Biotech will post -0.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on ALP shares. Weiss Ratings restated a “sell (e+)” rating on shares of Portage Biotech in a research report on Friday, July 24th. HC Wainwright began coverage on shares of Portage Biotech in a research report on Monday. They issued a “neutral” rating and a $0.25 price objective on the stock. Finally, Zacks Research raised shares of Portage Biotech to a “hold” rating in a research note on Tuesday. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Portage Biotech currently has a consensus rating of “Reduce” and a consensus price target of $0.25.

Key Headlines Impacting Portage Biotech

Here are the key news stories impacting Portage Biotech this week:

• Positive Sentiment: HC Wainwright assigned Portage Biotech a $0.25 price target, above the current price of approximately $0.15, implying potential upside if the company’s clinical and financial outlook improves. However, the firm’s rating remains Neutral. HC Wainwright Initiates Coverage on Portage Biotech
• Neutral Sentiment: Zacks Research upgraded Portage Biotech to a Hold rating. The change removes a more negative stance but does not represent a buy recommendation, likely limiting the immediate positive effect on ALP shares. Zacks Research Portage Biotech Rating
• Neutral Sentiment: HC Wainwright’s recent coverage reiterates a Neutral rating and a $0.25 target, providing a valuation reference but little evidence of a near-term catalyst. HC Wainwright Weighs in on Portage Biotech Q1 Earnings
• Negative Sentiment: HC Wainwright forecasts continued quarterly losses for fiscal 2027, including EPS of negative $0.10 in Q1 and negative $0.07 in Q2 and Q3, with a full-year loss of approximately $0.28 per share. The estimates reinforce concerns about Portage Biotech’s limited revenue base and need for additional funding.

About Portage Biotech

Portage Biotech (NASDAQ:ATON) is a biotechnology company focused on acquiring, developing and advancing therapeutic candidates and platform technologies. The company concentrates its development efforts primarily in areas such as oncology, immunology/inflammation and infectious disease, seeking to move programs from discovery and preclinical stages into clinical development through subsidiary companies and collaborative arrangements.

Portage structures its operations to support a diversified pipeline, advancing both small molecules and biologics by funding preclinical research, conducting clinical trials, and managing regulatory interactions.